Back to search results

Study of BMS-986482 for Advanced Solid Tumors

This study is looking at the safety and effectiveness of a drug called BMS-986482. It will be given alone or in combination with other drugs like Nivolumab, rHuPH20, Nivolumab/relatlimab/rHuPH20, or Bevacizumab. These treatments are for people with advanced solid tumors that have either spread or cannot be removed by surgery, and who have already tried other treatments or cannot receive them. The study aims to see how many participants experience side effects (adverse events) and serious side effects. The treatments work by targeting a 'checkpoint inhibitor' mechanism, which can help the body's immune system fight cancer. About 413 people are expected to join this study.

Study design
This is an interventional study for advanced solid tumors. It plans to enroll 413 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be monitored for adverse events for up to 135 days after their last treatment visit.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06697197

A Study of BMS-986482 Alone or as Combination Therapy in Participants With Advanced Solid Tumors

Recruiting
PHASE1Ages 18+InterventionalTreatment
Bristol-Myers Squibb
~413 participants
Updated 2026-02-03 on ClinicalTrials.gov
What's tested:BMS-986482Nivolumab and rHuPH20Nivolumab/relatlimab/rHuPH20Bevacizumab

At a glance

Recruiting sites
20 of 21 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)
Measured over Up to 135 days post last treatment visit
+4 more outcomes measured

Conditions

Advanced Solid Tumors

Explore related trials

Solid Neoplasm

NCT06697197

Where you'd take part

This study runs at 21 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Assistance Publique Hôpitaux de Marseille - Hôpital de la Timone

    Marseille, Bouches-du-Rhône, Francestudy coordinator listed

    Recruiting

  • Clinica Universidad de Navarra

    Pamplona, Navarre, Spainstudy coordinator listed

    Recruiting

  • Erasmus Medisch Centrum

    Rotterdam, Netherlandsstudy coordinator listed

    Recruiting

  • Fondazione IRCCS Istituto Nazionale dei Tumori

    Milan, Lombardy, Italystudy coordinator listed

    Recruiting

  • Fred Hutchinson Cancer Center

    Seattle, Washingtonstudy coordinator listed

    Recruiting

  • General Hospital of Athens "Laiko"

    Athens, Attikí, Greecestudy coordinator listed

    Recruiting

  • Gustave Roussy

    Villejuif, Paris, Francestudy coordinator listed

    Recruiting

  • Hospital Universitari Vall d'Hebron

    Barcelona, Barcelona [Barcelona], Spainstudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bristol-Myers Squibb · STUDY_DIRECTOR · Bristol-Myers Squibb

Who to contact

BMS Clinical Trials Contact Center www.BMSClinicalTrials.com
[email protected]
855-907-3286
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

All participants must have a histologically or cytologically confirmed, advanced, unresectable/metastatic, solid malignancy measurable by RECIST v1.1, and have received, be refractory to, ineligible for, intolerant of, or refused existing therapy(ies) known to provide clinical benefit for the condition of the participant.
Participant must be ≥ 18 years or the legal age of consent in the jurisdiction in which the study is taking place, inclusive, at the time of signing the ICF.

Exclusion

History of life threatening immune mediated toxicity related to prior T-cell agonist or checkpoint inhibitor therapy, except those that are unlikely to re-occur with standard countermeasures.
Any significant acute or chronic medical illness which would interfere with study intervention or follow-up in the opinion of the investigator.

What this trial measures

  • Number of participants with Adverse Events (AEs) as assessed by National Cancer Institute -Common Terminology Criteria for Adverse Events version 5.0 (NCI-CTCAE v5.0)Up to 135 days post last treatment visit
  • Number of participants with Serious AEs (SAEs) as assessed by NCI-CTCAE v5.0Up to 135 days post last treatment visit
  • Number of participants with AEs meeting protocol-defined Dose-Limiting Toxicity (DLT) criteria as assessed by NCI-CTCAE v5.0Up to Day 28
  • Number of participants with AEs leading to discontinuation as assessed by NCI-CTCAE v5.0Up to 135 days post last treatment visit
  • Number of deaths as assessed by NCI-CTCAE v5.0Through study completion (Up to 4 years)